


Product Name : Senexin B
Cat. No. : PC-42425
CAS No. : 1449228-40-3
Molecular Formula : C₂₇H₂₆N₆O
Molecular Weight : 450.53
Target : Cyclin-dependent Kinase (CDK)
Solubility : 10 mM in DMSO



Biological Activity

Senexin B (SNX2-1-165) is a highly potent, selective and orally available **CDK8/CDK19** inhibitor with IC₅₀ of 24-50 nM. Senexin B (SNX2-1-165) exhibits selectivity for CDK8 and CDK19 with K_d of 140 nM and 80 nM, respectively. Senexin B (SNX2-1-165) significantly suppresses tumor growth in ER-positive breast cancer xenografts.

References

Donald C. Porter, et al. Abstract PR08: Targeting tumor microenvironment with selective small-molecule inhibitors of CDK8/19.

Cdk8/cdk19 selective inhibitors and their use in anti-metastatic and chemopreventative methods for cancer. Publication number: WO2013116786 A1.

McDermott MS, et al. *Oncotarget*. 2017 Feb 21;8(8):12558-12575.

Caution: Product has not been fully validated for medical applications. Lab Use Only!

E-mail: tech@probechem.com